Search Results
Your search for ASCO matches 20849 pages
Showing 1751 - 1800The Role of U.S. Cancer Centers in Preparing Patients With Cancer for Climate Change Emergencies
Investigators have proposed that cancer centers may be uniquely positioned to protect communities and patients with cancer from climate-driven disasters by bolstering climate change–associated emergency preparedness, according to a recent study published by Espinel et al in the Journal of the...
Can an AI Model Improve Mortality Risk Prediction Linked to Lung Cancer or Cardiovascular Disease?
A novel artificial intelligence (AI) model may be able to accurately predict the risk of death from lung cancer, cardiovascular disease, and other causes by using data from low-dose computed tomography (CT) scans of the lungs, according to a recent study published by Xu et al in Radiology....
Selinexor as Maintenance Therapy for p53 Wild-Type Endometrial Cancer
Long-term follow-up of selinexor maintenance therapy in patients with p53 wild-type endometrial cancer has demonstrated anticancer activity, according to data presented by Brian M. Slomovitz, MD, and colleagues during the ASCO Plenary Series: July 2023 Session (Abstract 427956). Results of the...
Forced Displacement and Diagnosis of Cancer in Syrian Refugees
Syrian migrants, including refugees, may be more likely to be diagnosed with a more advanced stage of breast cancer at a younger age when compared with individuals from Jordan, according to a recent study published by Hazra et al in JAMA Network Open. The new findings suggest the trauma associated...
Vaccine Rollout May Reduce COVID-19–Related Mortality by 84% Among Patients With Cancer, Study Predicts
The rollout of COVID-19 vaccines may be an effective strategy for reducing COVID-19–related hospitalizations and mortality in patients with cancer, according to a recent study published by Starkey et al in Scientific Reports. Study Methods and Results In this study, investigators analyzed the...
Volume of Liver Resected During Gallbladder Surgery May Not Significantly Affect Overall Survival in Patients With Gallbladder Cancer
Investigators have found that overall survival rates may not vary significantly among patients with gallbladder cancer who have had different volumes of their livers resected, as long as the cancer is completely removed, according to a study published by Vega et al in the Annals of Surgical...
Study Explores Incidence and Mortality Rates of Cardiovascular Disease Among Black vs White Cancer Survivors
Black cancer survivors in the United States may experience a higher incidence of cardiovascular disease and associated mortality than White cancer survivors, according to a recent study published by Sung et al in the International Journal of Epidemiology. The investigators also found that...
Keeping Staff and Patients Safe From Workplace Violence
The statistics are chilling. According to estimates from the U.S. Bureau of Labor Statistics, workers in the fields of health care and social services are five times more likely to suffer from a workplace violence injury than workers overall.1 The Bureau statistics show that the rate of injuries...
ASCO Issues Statements on Recent U.S. Supreme Court Rulings on Affirmative Action, LGBTQ+ Rights
ASCO issued a statement regarding the U.S. Supreme Court decision on affirmative action on June 29. A statement from ASCO Chief Executive Officer, Clifford A. Hudis, MD, FASCO, FACP, follows: “[The] U.S. Supreme Court ruling on affirmative action threatens to reverse hard-won gains in diversity...
ASCO Blueprint Report Captures Steady Progress Toward Equity, Diversity, and Inclusion
The American Society of Clinical Oncology (ASCO) has released its first-ever Equity, Diversity, and Inclusion (EDI) Blueprint Report, highlighting ASCO’s 2022 advancements in the EDI space. The report provides information on 22 initiatives that ASCO launched across the mission pillars of research,...
Implementation of CLINICAL TREATMENT Act Advances, Increasing Access to Cancer Clinical Trials
After direct advocacy from the Association for Clinical Oncology (ASCO) and its members, in December 2019, Congress enacted the CLINICAL TREATMENT Act, which requires all states and territories to cover and reimburse routine costs of care for treating a Medicaid enrollee who is participating in a...
ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer
In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for...
Congress Sends ASCO-ASTRO–Supported Letter on Cancer Drug Shortages to the HHS and the FDA
As chemotherapy drug shortages continue to delay patient care and alter treatment plans, 70 bipartisan members of Congress sent a letter to the Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) asking for more information on the shortages and for ways...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...
Extended Follow-up of TROPiCS-02 Trial: Sacituzumab Govitecan in Metastatic Breast Cancer
Additional follow-up of the phase III TROPiCS-02 trial has upheld the progression-free and overall survival benefit seen with sacituzumab govitecan-hziy compared with physician’s choice of treatment in patients with endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast...
Investigators Evaluate the Effect of Body Mass Index on Outcomes in Patients With Head and Neck Cancer
Investigators reported that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those patients with a normal or obese BMI, according to a recent study...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
Expert Point of View: Daniel P. Petrylak, MD
“Clinically, the implications [of the THOR trial] are clear in that all metastatic urothelial cancers should be tested for FGFR mutations,” stated invited discussant Daniel P. Petrylak, MD, of Yale School of Medicine. “This should be done at the beginning of treatment for metastatic disease, as it...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Expert Point of View: Corey Speers, MD, PhD, and Julie R. Gralow, MD, FACP, FASCO
ASCO expert Corey Speers, MD, PhD, Professor of Radiation Oncology at the University Hospitals Seidman Cancer Center, Cleveland, provided thoughts on the IELSG37 trial at a press briefing. “The investigators should be congratulated for running the largest ever trial in primary mediastinal B-cell...
Omitting Mediastinal Radiotherapy in Some Patients With Primary Mediastinal B-Cell Lymphoma After Immunochemotherapy
In the largest prospective study of patients with primary mediastinal B-cell lymphoma, radiation therapy was omitted in complete responders to immunochemotherapy without compromising outcomes. These findings were presented at the 2023 ASCO Annual Meeting.1 “Mediastinal radiotherapy may be safely...
Novel Imaging-Guided Radiotherapy Technique May Reduce Short-Term Side Effects for Patients With Prostate Cancer
The use of magnetic resonance (MR)-guided daily adaptive stereotactic body radiotherapy (SBRT) might make radiation therapy safer for patients with prostate cancer than standard computed tomography (CT)-guided SBRT by helping clinicians more accurately target the prostate while avoiding nearby...
Improving Screening and Surveillance Practices for Early Cancer Detection in Patients With Barrett’s Esophagus
A recent study published in Gastroenterology by Wani et al found that at least a quarter of all esophageal adenocarcinomas may be detected within a year of a negative upper endoscopy in patients with newly diagnosed Barrett's esophagus. The investigators proposed methods for improving the efficacy...
Olaparib and Temozolomide in Advanced Uterine Leiomyosarcoma
In a phase II trial (NCI Protocol 10250) reported in the Journal of Clinical Oncology, Ingham et al found that the combination of olaparib and temozolomide showed activity in previously treated patients with advanced uterine leiomyosarcoma. Study Details In the multicenter trial, 22 evaluable...
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
FDA Approves Quizartinib for Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
On July 20, the U.S. Food and Drug Administration (FDA) approved quizartinib (Vanflyta) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adults with newly diagnosed acute...
Expert Point of View: Nabil F. Saba, MD, FACP, and Jennifer Choe, MD, PhD
Nabil F. Saba, MD, FACP, Professor and Vice Chair of Hematology and Medical Oncology, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, and Director of the HNCA Medical Oncology Program at the Winship Cancer Institute, Emory University, Atlanta, was invited to discuss the...
JUPITER-02: Toripalimab Plus Chemotherapy Improved Survival Outcomes for Some Patients With Advanced Nasopharyngeal Carcinoma
In the final overall survival analysis of the phase III JUPITER-02 trial, first-line treatment with toripalimab plus gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs chemotherapy alone in...
Psilocybin and Other Psychedelics May Help Patients With Late-Stage Gynecologic Cancer Tackle Mental Health Symptoms
Investigators revealed that psilocybin-assisted psychotherapy and other psychedelics may effectively ease symptoms of anxiety and depression in patients with late-stage gynecologic cancers, according to a new commentary published by Yaniv et al in the International Journal of Gynecological Cancer. ...
Biological Aging and Radiation Therapy for Breast Cancer
Some patients who have received treatment for breast cancer may experience increased biological aging compared with those who have never been diagnosed with breast cancer, according to a new study published by Kresovich et al in the Journal of the National Cancer Institute. The findings showed that ...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Current Management of and Future Possibilities for Triple-Negative Breast Cancer
“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...
Turning Fear Into Hope
The first sign that pancreatic cancer was stalking my family was in 1982, when my mother was diagnosed with stage IV disease. She was just 54 years old and died several months later. After two more family members in their early 50s were also diagnosed with the cancer, I began to worry that I would...
Investigators Offer Guidance for Improving Access to Oncology Drugs in Sub-Saharan Africa
Investigators have addressed the need to improve access to oncology drugs designed to increase the survival and quality of life of patients in sub-Saharan Africa and combat the significant health-care disparities many of these patients continue to face, according to a new study published by Sharma...
Diversity May Play a Key Role in Black Patients’ Trust of Videos About Prostate Cancer
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
SSO Names Chandrakanth Are, MBBS, MBA, Chief Executive Officer of Global Forum of Cancer Surgeons
As a member of the Global Forum of Cancer Surgeons, the Society of Surgical Oncology (SSO) is pleased to announce that Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, has been named Chief Executive Officer of the Global Forum of Cancer Surgeons. Dr. Are holds the title of Jerald L. and Carolynn J....
ASCO Remembers Former Board of Directors Member and Radiation Oncologist A. William Blackstock, Jr, MD, FASCO
ASCO is deeply saddened by the death of A. William Blackstock, Jr, MD, FASCO, who served on the Society’s Board of Directors from 2018 to 2022. Dr. Blackstock passed away on June 18, 2023, from complications of prostate cancer. He was 60 years old. “We mourn the passing of a friend and colleague...
Study of Cancer Metastasis Receives $35 Million Boost at Johns Hopkins Medicine
With a $35 million gift from researcher, philanthropist, and race car driver Theodore Giovanis, FHFMA, MBA, scientists at Johns Hopkins Medicine will study the biologic roots of the most fatal aspect of cancer: how it metastasizes through the body. The contribution, which is a 15-year commitment,...
Damon Runyon Names Physician-Scientist Awardees
Three scientists who are researching novel approaches to the treatment of cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award: Nicole M. Cruz, MD; Mounica Vallurupalli, MD; and Nina Weichert-Leahey, MD. The awardees were selected through a highly...
Berberine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the use of...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Allison Institute Announces Appointment of Inaugural Members
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center has announced the appointment of its first members, including pioneering researchers who have made notable contributions to science as well as rising stars on the path toward important breakthroughs. This group will ...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...
Study Examines Impact of Modified Treatment Protocols on Survival in Pediatric Patients With ALL
The 5-year survival rate of pediatric patients with acute lymphoblastic leukemia (ALL) has continued to increase to 94%, according to a new study published by Pieters et al in the Journal of Clinical Oncology. Background ALL is the most common form of pediatric cancer in the Netherlands—with about...
Neoadjuvant and Adjuvant GVAX Plus Nivolumab and Urelemab May Increase Immune Response in Patients With Resectable Pancreatic Cancer
A combination of the pancreatic cancer vaccine GVAX, the immune checkpoint inhibitor nivolumab, and the anti-CD137 agonist antibody urelemab may be safe and increase the amount of immune T cells in the tumors of patients with operable pancreatic cancer when given 2 weeks prior to surgical tumor...
Expert Point of View: Barbara Burtness, MD
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
